ImmunoGen Inc - Company Profile
Powered by 
All the data and insights you need on ImmunoGen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date ImmunoGen Inc Strategy Report
- Understand ImmunoGen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGen incorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
830 Winter Street, Waltham, Massachusetts, 02451-1477
Website
www.immunogen.com
Telephone
1 781 8950600
No of Employees
277
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$108.8M
ImmunoGen Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Mirvetuximab soravtansine: for ovarian cancer. |
| IMGN632: for Acute myeloid leukemia (AML), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In October, the company announced that the European Medicines Agency accepted the Marketing Authorization Application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
| 2023 | Financing Agreements | In April, the company entered into a term loan financing facility for up to US$175 million with entities managed by Pharmakon Advisors. |
| 2023 | Contracts/Agreements | In March, the company entered into an agreement with Vertex Pharmaceuticals under which Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target. |
Competitor Comparison
| Key Parameters | ImmunoGen Inc | F. Hoffmann-La Roche Ltd | Pfizer Inc | AbbVie Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United Kingdom |
| City | Waltham | Basel | New York | North Chicago | Cambridge |
| State/Province | Massachusetts | - | New York | Illinois | England |
| No. of Employees | 277 | 103,605 | 88,000 | 50,000 | 89,900 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephen C. McCluski | Chairman | Executive Board | 2009 | 70 |
| Mark J. Enyedy | Chief Executive Officer; Director; President | Executive Board | 2016 | 59 |
| Lauren White | Chief Financial Officer; Senior Vice President | Senior Management | 2023 | - |
| Daniel Char | Senior Vice President; Chief Legal Officer | Senior Management | 2022 | - |
| Stacy A. Coen | Chief Business Officer; Senior Vice President | Senior Management | 2020 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward